David Taber to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications David Taber has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.453
-
Cytolytic Induction Therapy Improves Clinical Outcomes in African-American Kidney Transplant Recipients. Ann Surg. 2017 09; 266(3):450-456.
Score: 0.130
-
Induction therapy: clinical and quality of life outcomes in aged renal transplant recipients. Clin Transplant. 2015 Mar; 29(3):222-6.
Score: 0.109
-
Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation. Ann Surg. 2014 May; 259(5):888-93.
Score: 0.103
-
Long-term efficacy of induction therapy with anti-interleukin-2 receptor antibodies or thymoglobulin compared with no induction therapy in renal transplantation. Transplant Proc. 2008 Dec; 40(10):3401-7.
Score: 0.071
-
Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77. Clin Lung Cancer. 2013 May; 14(3):224-9.
Score: 0.023
-
Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation. Clin Transplant. 2010 Jan-Feb; 24(1):40-7.
Score: 0.018